Allogene Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 18, 2026, and June 22, 2026. The filing details the results of the Company's 2026 Annual Meeting of Stockholders and the initiation of a new equity offering.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to a planned equity offering of up to $135.0 million.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation, increasing authorized common stock from 400,000,000 to 800,000,000 shares. This became effective on June 18, 2026.
- Equity Offering: On June 22, 2026, the Company filed a prospectus supplement to sell up to $135.0 million of common stock under an existing Sales Agreement with TD Securities (U.S.A.) LLC.
- Director Elections: Stockholders elected Deborah Messemer, Vicki Sato, Ph.D., and Owen Witte, M.D. as Class II Directors. Dr. Witte received a higher percentage of withheld votes compared to the other nominees.
- Executive Compensation: Stockholders approved the advisory compensation of Named Executive Officers and voted to hold future say-on-pay votes annually.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the standard disclosures associated with the equity offering and corporate governance votes.
Investor Verification Checklist
- Verify the impact of the $135.0 million equity offering on existing shareholder dilution.
- Review the definitive proxy statement (Schedule 14A) filed on April 30, 2026, for detailed executive compensation data.
- Monitor the utilization of the newly authorized 400,000,000 additional shares.
- Check subsequent filings for the actual volume and pricing of shares sold under the TD Securities Sales Agreement.